PAREXEL TO OFFER SIGNIFICANT INDUSTRY INSIGHTS AT 19TH ANNUAL DRUG INFORMATION ASSOCIATION EURO MEETING
BOSTON, MA, March 22, 2007 — Several experts from PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services provider, will present key topics at the Drug Information Association’s (DIA) 19th Annual EuroMeeting in Vienna, Austria, being held March 26 – 28, 2007. Attendees will benefit from presentations by some of PAREXEL’s thought leaders, selected by the DIA to address industry issues including borderline products, current and future challenges of biosimilars, genotoxic impurities, and global expanded access programs.
PAREXEL experts will present or chair the following sessions:
Tuesday, March 27:
- Borderline Medicine/Cosmetics – Peter Lassoff, Vice President Europe, PAREXEL Consulting (14:00 – 15:30)
Wednesday, March 28:
- Current and Future Challenges of Biosimilars from a Consultant’s Point of View, Covering Experience from the EU, US and Elsewhere – Cecil Nick, Director, PAREXEL Consulting (09:00 – 10:30)
- Residues of Genotoxic Alkyl Mesylates in Mesylate Salt Drug substances: Real or Imaginary Problems? – David Snodin, Vice President Non-Clinical, PAREXEL Consulting (14:00 – 15:30)
- Managing the Key Challenges of Running Global Expanded-Access Programmes – Anne-Yvonne Kermabon, Associate Project Director, Clinical Research Services, PAREXEL (16:00 – 17:30)
For the past 25 years, clients have relied on PAREXEL to provide integrated clinical development, regulatory affairs consulting and commercialization services, as well as to offer technologies that expedite time-to-market. Attendees at the DIA Euro meeting can visit PAREXEL’s Booth #120 in the exhibit hall to discuss these areas or to view a demonstration of advanced technologies, including clinical trial management systems and drug supply forecasting and visualization software provided by PAREXEL’s subsidiary, Perceptive Informatics.
DIA's 19th Annual EuroMeeting is global in scope, attracting more than 2,600 industry professionals from more than 50 countries. This meeting brings together professionals from the bio/pharmaceutical industry, contract service organizations, academic research centers and regulatory agencies. With more than 130 sessions in 24 tracks, the annual event covers a variety of cross-disciplinary topics, from regulatory compliance to information technology to project management and outsourcing.
For more information about PAREXEL visit www.PAREXEL.com or Booth #120 at the DIA EuroMeeting.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 56 locations throughout 43 countries around the world, and has over 6,215 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2006 as filed with the SEC on February 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.